A water-soluble dietary fiber and its use in the preparation of a medicament for promoting the metabolism of ellagic acid into urolithin a and a pharmaceutical composition

Abstract

The application provides a water-soluble dietary fiber and application of the water-soluble dietary fiber in preparation of a medicine for promoting metabolism of ellagic acid into urolithin A and a medicine composition, and belongs to the technical field of biological medicines.The water-soluble dietary fiber provided by the application comprises at least two components: gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin.In the application, the water-soluble dietary fiber and ellagic acid in different combinations are compounded to feed mice, and the average content of urolithin A in the feces of the mice can be significantly improved.It can be seen that the water-soluble dietary fiber or the combination of the water-soluble dietary fiber and ellagic acid can improve the metabolic type of the body ellagic acid and increase the content of urolithin A, thereby providing a new means for the treatment of diabetes, obesity, aging and central nervous system diseases.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of biological medicine technology, and particularly relates to a water-soluble dietary fiber and application of the water-soluble dietary fiber in preparation of a medicine for promoting metabolism of ellagic acid into urolithin A and a pharmaceutical composition. BACKGROUND

[0002] Ellagic acid is a natural polyphenol, which exists in the form of ellagitannin in berries (pomegranate, strawberry, etc.) and nuts (walnut, chestnut, etc.) in nature, has a wide source and is easy to extract. In the gastrointestinal tract, ellagitannin is hydrolyzed to release hexahydroxybenzene and is rapidly condensed into ellagic acid. Ellagic acid is a strong polar molecule and is almost impossible to be absorbed and utilized by the gastrointestinal tract. Therefore, ellagic acid itself has low bioavailability and cannot exert effective biological activity. The specific flora in the human intestinal tract can effectively metabolize ellagic acid and produce a series of urolithins. Compared with ellagic acid, urolithins can be effectively utilized and produce a series of beneficial activities. Japanese patent JP2022190124 shows that urolithin A can exert beneficial activities in mouse models of diabetes, obesity, aging and central nervous system diseases. Therefore, as a precursor of urolithins, ellagic acid is widely concerned in the food field due to its wide source and easy extraction.

[0003] Previous studies have shown that ellagic acid can be metabolized in the colon to produce different urolithin derivatives. Among them, urolithin A, isomer urolithin A and urolithin B are the end products of ellagic acid metabolism. According to the different end products of EA metabolism in different populations, the metabolic types of ellagic acid in different populations can be divided into type A, type B and type 0; type A population produces urolithin A as the final product, type B population produces urolithin A, urolithin B and isomer urolithin A, and type 0 population cannot metabolize ellagic acid to produce urolithin (Tomás-Barberán F A, Garcia-Villalba R, Gonzalez-Sarrias A, et al. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status [J]. Journal of Agricultural and Food Chemistry, 2014, 62(28): 6535-6538.). Therefore, in type 0 population, ellagic acid cannot be metabolized to produce effective beneficial activity of urolithin A, and in type B population, the production of urolithin A is reduced and cannot reach the effective dose. This limits the application of ellagic acid in type 0 and type B populations. The difference in end product metabolism in different populations is mainly related to the difference in the composition of the intestinal flora of different populations, so it is urgent to develop a method to improve the metabolic conversion of ellagic acid in type 0 and type B populations.

[0004] Compound with polysaccharide can effectively improve the biological activity of ellagic acid: CN113812629 discloses a preparation method of a starch-ellagic acid package combination and its application in antioxidant food, which forms a combination by high-speed grinding ellagic acid and starch. The combination has good sustained-release performance and in vitro antioxidant activity. CN115191540 discloses a composition containing ellagic acid and its preparation method and use, which uses chitosan oligosaccharide, inulin and ellagic acid to prepare a compound, which can effectively inhibit the growth of gastric cancer cells and intestinal cancer cells. CN111107908 discloses a composition comprising an ellagic acid compound, which uses different glycerophospholipids and metal oxides to compound with ellagic acid to improve the antioxidant activity of ellagic acid and improve the stability of the whole composition. However, there is no report on the compound of polysaccharide and ellagic acid to promote the metabolism of ellagic acid.

[0005] Dietary fiber is a recognized human health nutrient. Previous studies have shown that dietary fiber plays an important role in gastrointestinal health by regulating the gut microbiota. In addition, mechanism studies have shown that the physiological functions of different dietary fibers depend largely on their physicochemical properties, one of which is solubility. Compared with insoluble dietary fiber, soluble dietary fiber is easily accessible and metabolized by fiber-degrading microorganisms in the intestine, and produces a series of beneficial and functional metabolites. Given that the effect of ellagic acid on the metabolism of urolithin A in vivo is low, and there is currently no report on dietary fiber that can improve the metabolism of ellagic acid to urolithin A. SUMMARY

[0006] Therefore, the purpose of the present application is to provide a water-soluble dietary fiber that improves the structure of the intestinal flora by combining different types of soluble dietary fiber, thereby improving the efficiency of ellagic acid metabolism to urolithin A.

[0007] The present application provides a water-soluble dietary fiber, comprising at least two components: gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin.

[0008] Preferably, it comprises at least one group: a first water-soluble dietary fiber formed by gellan gum, guar gum and carrageenan, a second water-soluble dietary fiber formed by fructooligosaccharide, xylooligosaccharide and isomaltooligosaccharide, a third water-soluble dietary fiber formed by pectin, beta-glucan and polydextrose, a fourth water-soluble dietary fiber formed by sodium alginate, gum arabic and resistant dextrin, and a fifth water-soluble dietary fiber formed by xanthan gum, tragacanth gum and inulin.

[0009] The mass ratio of the three components in the first water-soluble dietary fiber, the second water-soluble dietary fiber, the third water-soluble dietary fiber, the fourth water-soluble dietary fiber or the fifth water-soluble dietary fiber is 1-3: 1-3: 1-3, respectively.

[0010] The present application provides a pharmaceutical composition for promoting the metabolism of ellagic acid to urolithin A, comprising the water-soluble dietary fiber and ellagic acid.

[0011] The mass ratio of the water-soluble dietary fiber and ellagic acid is (100-250): 3.

[0012] Preferably, the mass ratio of the water-soluble dietary fiber and ellagic acid is 250: 3.

[0013] Preferably, the structural formula of the ellagic acid is shown as formula I:

[0014]

[0015] The application provides application of the water-soluble dietary fiber or the pharmaceutical composition in preparation of a medicine for promoting metabolism of tannic acid into urolithin A.

[0016] The application provides a product for promoting metabolism of tannic acid into urolithin A, which takes the water-soluble dietary fiber or the pharmaceutical composition as an active ingredient, and further comprises an excipient.

[0017] Preferably, the product comprises at least one of the following: a medicine, a health product and a health food.

[0018] The application provides application of the water-soluble dietary fiber or the pharmaceutical composition in preparation of a medicine for preventing and / or treating at least one of the following diseases: diabetes, obesity, aging and central nervous system diseases.

[0019] Preferably, the patient of the disease belongs to a tannic acid metabolism type A population, a type B population and / or a type 0 population.

[0020] The application provides a water-soluble dietary fiber, which comprises at least two components: gellan gum, guar gum, carrageenan, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin. The application obtains a plurality of components with an influence on the tannic acid metabolism type through screening optimization from a plurality of water-soluble dietary fibers. In the application, the above different types of water-soluble dietary fibers and tannic acid are combined to feed mice, and the metabolism of tannic acid in the mice is monitored. The results show that the average content of urolithin A in the feces of the mice is increased from 41.0-32.3 μg / g of feces (control group, only fed with tannic acid) to 41.4-87.4 μg / g of feces. It can be seen that the combination of different types of water-soluble dietary fibers is beneficial to increase the level of tannic acid metabolism into urolithin A in the body, which provides a new means for treating a plurality of diseases through urolithin A, and has important clinical disease treatment significance.

[0021] Further, the application specifically limits a plurality of combination schemes of water-soluble dietary fibers. The influence degrees of the combination of different types of water-soluble dietary fibers on the tannic acid metabolism type are different. Among them, the fifth water-soluble dietary fiber formed by xanthan gum, tragacanth gum and inulin has the best effect on increasing the content of tannic acid metabolism into urolithin A, and the second water-soluble dietary fiber formed by fructo-oligosaccharide, xylo-oligosaccharide and isomalto-oligosaccharide is the second. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 The screening results of the water-soluble dietary fiber with promoting metabolism of tannic acid into urolithin A;

[0023] Figure 2Figure showing the content change of ellagic acid metabolized into urolithin A promoted by water-soluble dietary fibers in different combinations in Examples 2, 3, 4, 5 and 6; compared with the control group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. DETAILED DESCRIPTION

[0024] The present application provides a water-soluble dietary fiber, comprising at least two components: gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin.

[0025] In the present application, the water-soluble dietary fiber preferably comprises at least one group of: the first water-soluble dietary fiber formed by gellan gum, guar gum and carrageenan, the second water-soluble dietary fiber formed by fructooligosaccharide, xylooligosaccharide and isomaltooligosaccharide, the third water-soluble dietary fiber formed by pectin, beta-glucan and polydextrose, the fourth water-soluble dietary fiber formed by sodium alginate, gum arabic and resistant dextrin, and the fifth water-soluble dietary fiber formed by xanthan gum, tragacanth gum and inulin, more preferably the second water-soluble dietary fiber and the fifth water-soluble dietary fiber, and most preferably the fifth water-soluble dietary fiber. The mass ratio of the three components in the first water-soluble dietary fiber, the second water-soluble dietary fiber, the third water-soluble dietary fiber, the fourth water-soluble dietary fiber or the fifth water-soluble dietary fiber is preferably 1-3: 1-3: 1-3 in turn, and more preferably 1: 1: 1. The present application does not have special restrictions on the source of the above-mentioned water-soluble dietary fiber, and any source of water-soluble dietary fiber known to those skilled in the art can be used. In the examples of the present application, the gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin are purchased from Sigma.

[0026] In the examples of the present application, a large number of water-soluble dietary fibers are screened and it is found that the combination of different water-soluble dietary fibers can significantly affect the efficiency of ellagic acid metabolized into urolithin A. For example, from 20 dietary fibers of gellan gum, guar gum, carrageenan, agar, gelatin, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, galactooligosaccharide, pectin, chitosan, beta-glucan, polydextrose, xylan, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin, animal experiments are screened and it is found that 15 dietary fibers of gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin can promote the metabolism of ellagic acid in mice.

[0027] The present application provides a pharmaceutical composition for promoting the metabolism of ellagic acid into urolithin A, comprising the water-soluble dietary fiber and ellagic acid; the mass ratio of the water-soluble dietary fiber and ellagic acid is (100-250):3. The mass ratio of the water-soluble dietary fiber and ellagic acid is preferably 250:3.

[0028] In the present application, in the pharmaceutical composition, the water-soluble dietary fiber improves the structure of intestinal probiotics in the body, thereby improving the efficiency of the metabolism of ellagic acid into urolithin A. The ellagic acid exists as a metabolic substrate. The ellagic acid can be extracted from one or more of pomegranate, blackberry, strawberry, pomegranate, medlar, raspberry, white acorn, cranberry, and hickory. The structural formula of the ellagic acid is preferably shown as formula I, which is purchased from Sigma Company.

[0029]

[0030] The present application provides the use of the water-soluble dietary fiber or the pharmaceutical composition in the preparation of a medicine for promoting the metabolism of ellagic acid into urolithin A.

[0031] The results of the embodiments of the present application prove that when the gellan gum, guar gum, and carrageenan are combined with ellagic acid to feed mice, the average content of urolithin A in the feces of mice is increased from 31.9 μg / g of feces to 59.1 μg / g of feces; when the pectin, β-glucan, and polydextrose are combined with ellagic acid to feed mice, the average content of urolithin A in the feces of mice is increased from 31.9 μg / g of feces to 63.5 μg / g of feces. When the sodium alginate, gum arabic, and resistant dextrin are combined with ellagic acid to feed mice, the average content of urolithin A in the feces of mice is increased from 31.9 μg / g of feces to 62.4 μg / g of feces. When the fructooligosaccharides, xylooligosaccharides, and isomaltooligosaccharides are combined with ellagic acid to feed mice, the average content of urolithin A in the feces of mice is increased from 31.9 μg / g of feces to 77.1 μg / g of feces. When the xanthan gum, tragacanth gum, and inulin are combined with ellagic acid to feed mice, the average content of urolithin A in the feces of mice is increased from 31.9 μg / g of feces to 87.4 μg / g of feces.

[0032] The present application provides a product for promoting the metabolism of ellagic acid into urolithin A, taking the water-soluble dietary fiber or the pharmaceutical composition as the active ingredient, and further comprising excipients.

[0033] In the present application, preferably, the product comprises at least one of the following: a medicine, a health product and a health food. In the embodiments of the present application, the pharmaceutical composition is added as an additive to animal feed to prepare a medicine feed capable of promoting the metabolism of ellagic acid to urolithin A. In the present application, the medicine is preferably provided to the human population in a daily dose of ellagic acid not less than 5 mg / kg of body weight. The ellagic acid is provided to mice in a daily dose of 60 mg / kg of body weight, and the water-soluble dietary fiber is provided to mice in a daily dose of 5000 mg / kg of body weight.

[0034] In view of the therapeutic purposes of various diseases that can be achieved by urolithin A, the present application provides the use of the water-soluble dietary fiber or the pharmaceutical composition in the preparation of a medicine for preventing and / or treating at least one of the following diseases: diabetes, obesity, aging and central nervous system disorders.

[0035] In the present application, the patients with the diseases preferably belong to the ellagic acid metabolism type A population, type B population and / or type 0 population.

[0036] The present application does not have special restrictions on the dosage form and preparation method of the medicine, and the dosage form and preparation method of the medicine known in the art can be used.

[0037] The water-soluble dietary fiber provided by the present application and the use thereof in the preparation of a medicine for promoting the metabolism of ellagic acid to urolithin A and the pharmaceutical composition are described in detail below in conjunction with the embodiments, but they should not be understood as limiting the scope of protection of the present application.

[0038] Example 1

[0039] Method for optimizing and screening components with the function of promoting the metabolism of ellagic acid to urolithin A from a plurality of water-soluble dietary fibers

[0040] Select 168 SPF C57BL / 6 mice with metabolism type A, and use Ain93G purified feed as the basic feed. The addition ratio of ellagic acid is 0.06%, and the addition ratio of gellan gum, guar gum, carrageenan, agar, gelatin, fructooligosaccharide, xylooligosaccharide, isomalto-oligosaccharide, galactooligosaccharide, pectin, chitosan, β-glucan, polydextrose, xylan, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin is 5%. The mice are randomly divided into 21 groups (n=8), and the control group is fed with Ain93G feed containing only ellagic acid for 7 days. The remaining groups are respectively fed with mixed feed containing ellagic acid and one of the above-mentioned dietary fibers for 7 days. The feces of the mice are collected on the last day of the experiment, and the metabolism of the mice is monitored.

[0041] Results show that 20 kinds of dietary fiber such as gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, pectin, beta-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum and inulin can effectively promote the metabolism of ellagic acid in mice.

[0042] Example 2

[0043] Gellan gum, guar gum and carrageenan combined with ellagic acid

[0044] Select 40 SPF C57BL / 6 mice, use Ain93G purified feed as the basic feed. The addition ratio of ellagic acid is 0.06%, and the addition ratio of gellan gum, guar gum and carrageenan is 5%. In the first 7 days, the mice are fed with Ain93G feed containing only ellagic acid every day, and in the next 7 days, the mice are fed with feed containing gellan gum, guar gum, carrageenan (mass ratio 1:1:1) and ellagic acid every day. Collect mouse feces every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. Add dimethyl sulfoxide to the mouse feces at a mass-volume ratio of 1:10, grind the mixture thoroughly, centrifuge at 4°C and 8000 rpm for 10 min, and then pass the supernatant through a 0.22 μm organic membrane for HPLC detection. The HPLC detection method of urolithin A is as follows:

[0045] The liquid chromatograph is Waters e2695 chromatograph, the detector is Waters 2489 ultraviolet-visible light detector, the detection wavelength is 305 nm, the chromatographic column is Eclipse XDB-C18 chromatographic column (250 mm x 4.6 mm, 5.0 μm; Agilent), the column temperature is 30°C, the injection amount is 10 μL, and the elution speed is 1.0 mL / min;

[0046] The mobile phase is 0.5% formic acid aqueous solution (A) and acetonitrile (B). That is, A is composed of 0.5% formic acid and 99.5% double distilled water, and B is composed of 100% acetonitrile, % being volume %;

[0047] The elution gradient is: 0-20 min, 5%-25% B; 20-25 min, 25%-70% B; 25-26 min, 70%-5% B; 26-35 min, 5% B.

[0048] Results show that the average content of urolithin A in mouse feces increased from 32.3 μg / g feces to 59.1 μg / g feces (p<0.05).

[0049] Example 3

[0050] Fructooligosaccharide, xylooligosaccharide and isomaltooligosaccharide combined with ellagic acid

[0051] Forty SPF C57BL / 6 mice were selected and used Ain93G purified feed as the basic feed. The addition ratio of ellagic acid was 0.06%, and the addition ratio of fructooligosaccharide, xylooligosaccharide and isomaltooligosaccharide was 5%. In the first 7 days, the mice were fed with Ain93G feed containing only ellagic acid every day, and in the following 7 days, the mice were fed with mixed feed containing fructooligosaccharide, xylooligosaccharide, isomaltooligosaccharide (mass ratio 1:1:1) and ellagic acid every day. The feces of mice were collected every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. The HPLC detection method of urolithin A was the same as that in Example 2.

[0052] The results showed that the average content of urolithin A in the feces of mice increased from 30.3 μg / g of feces to 77.1 μg / g of feces (p<0.0001).

[0053] Example 4

[0054] Pectin, β-glucan, polydextrose combined with ellagic acid

[0055] Forty SPF C57BL / 6 mice were selected and used Ain93G purified feed as the basic feed. The addition ratio of ellagic acid was 0.06%, and the addition ratio of pectin, β-glucan and polydextrose was 5%. In the first 7 days, the mice were fed with Ain93G feed containing only ellagic acid every day, and in the following 7 days, the mice were fed with mixed feed containing pectin, β-glucan and polydextrose (mass ratio 1:1:1) and ellagic acid every day. The feces of mice were collected every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. The HPLC detection method of urolithin A was the same as that in Example 2.

[0056] The results showed that the average content of urolithin A in the feces of mice increased from 14.0 μg / g of feces to 63.5 μg / g of feces (p<0.01).

[0057] Example 5

[0058] Sodium alginate, gum arabic, resistant dextrin combined with ellagic acid

[0059] Forty SPF C57BL / 6 mice were selected and used Ain93G purified feed as the basic feed. The addition ratio of ellagic acid was 0.06%, and the addition ratio of sodium alginate, gum arabic and resistant dextrin was 5%. In the first 7 days, the mice were fed with Ain93G feed containing only ellagic acid every day, and in the following 7 days, the mice were fed with mixed feed containing sodium alginate, gum arabic and resistant dextrin (mass ratio 1:1:1) and ellagic acid every day. The feces of mice were collected every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. The HPLC detection method of urolithin A was the same as that in Example 2.

[0060] The average content of urolithin A in mouse feces was found to increase from 22.5 pg / g feces to 62.4 pg / g feces (p<0.05).

[0061] Example 6

[0062] Xanthan gum, tragacanth gum, inulin, and ellagic acid combination

[0063] Forty SPF C57BL / 6 mice were selected and fed with Ain93G purified feed as the basic feed. The addition ratio of ellagic acid was 0.06%, and the addition ratio of xanthan gum, tragacanth gum, and inulin was 5%. In the first 7 days, the mice were fed with Ain93G feed containing only ellagic acid every day, and in the following 7 days, the mice were fed with a mixture of xanthan gum, tragacanth gum, and inulin (mass ratio 1:1:1) and ellagic acid every day. The feces of the mice were collected every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. The HPLC detection method of urolithin A was the same as that in Example 2.

[0064] The results showed that the average content of urolithin A in mouse feces increased from 23.4 pg / g feces to 87.4 pg / g feces (p<0.05).

[0065] Example 7

[0066] Inulin, polydextrose, sodium alginate, and ellagic acid combination

[0067] Forty SPF C57BL / 6 mice were selected and fed with Ain93G purified feed as the basic feed. The addition ratio of ellagic acid was 0.06%, and the addition ratio of inulin, polydextrose, and sodium alginate was 5%. In the first 7 days, the mice were fed with Ain93G feed containing only ellagic acid every day, and in the following 7 days, the mice were fed with a mixture of inulin, polydextrose, and sodium alginate (mass ratio 1:1:1) and ellagic acid every day. The feces of the mice were collected every 7 days during the experiment to monitor the metabolism of ellagic acid in mice. The HPLC detection method of urolithin A was the same as that in Example 2.

[0068] The results showed that the average content of urolithin A in mouse feces increased from 19.8 pg / g feces to 41.4 pg / g feces (p<0.05).

[0069] Example 8

[0070] Carrageenan, fructooligosaccharide, pectin, and ellagic acid combination

[0071] Select 40 SPF C57BL / 6 mice, using Ain93G purified feed as the basic feed. The addition ratio of ellagic acid is 0.06%, the addition ratio of carrageenan, fructooligosaccharide, pectin is 5%, the first 7 days every day feeding only contains ellagic acid Ain93G feed, after 7 days, every day feeding mixed feed of carrageenan, fructooligosaccharide, pectin (mass ratio is 1:1:1) and ellagic acid. Collect mouse feces every 7 days during the experiment, monitor the mouse ellagic acid metabolism. The HPLC detection method of urolithin A is the same as example 2.

[0072] The results show that the average content of urolithin A in mouse feces is increased from 31.9 μg / g feces to 43.7 μg / g feces (p<0.05).

[0073] The above only describes the preferred embodiments of the present application, it should be noted that for those skilled in the art, without departing from the principles of the present application, can make a number of improvements and refinements, these improvements and refinements should also be considered as the protection scope of the present application.

Claims

1. A pharmaceutical composition for promoting the metabolism of ellagic acid to urolithin A, characterized in that, consisting of water-soluble dietary fiber and ellagic acid; the water-soluble dietary fiber consists of pectin, beta-glucan and polydextrose; the mass ratio of the pectin, beta-glucan and polydextrose is 1-3:1-3:1-3; the mass ratio of the water-soluble dietary fiber and ellagic acid is (100-250):

3.

2. The pharmaceutical composition according to claim 1, wherein the mass ratio of the water-soluble dietary fiber and ellagic acid is 250:

3.

3. A product for promoting the metabolism of ellagic acid to urolithin A, characterized in that, a pharmaceutical composition as claimed in claim 1 as an active ingredient, and a pharmaceutically acceptable carrier.

4. The product of claim 3, wherein, the product comprises a medicine and / or a health product.

Images